UnicoCell Biomed Co., Ltd.

As of June 30, 2026, UnicoCell Biomed Co., Ltd. carries a market capitalization of 5.06B, placing it among publicly traded companies globally. Its enterprise value stands at 4.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

UnicoCell Biomed Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, UnicoCell Biomed Co., Ltd. has 63.64M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, UnicoCell Biomed Co., Ltd. maintains a current ratio of 36.82, meaning it holds 36.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, UnicoCell Biomed Co., Ltd.'s stock has declined approximately 2.00% over the past 52 weeks. The 50-day moving average sits at 73.49, while the 200-day moving average is 80.12.

As of June 30, 2026, UnicoCell Biomed Co., Ltd. holds 709.96M in cash and equivalents against 58.86M in total debt, resulting in a net debt position of -46.55M. Total book value stands at 818.63M, with working capital of 723.77M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

UnicoCell Biomed Co., Ltd.'s most recent stock split took place on February 9, 2022.